Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases

Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q

April 24, 2018 8:48 AM EDT

Piper Jaffray reiterated an Overweight rating and $407.00 price target on Biogen (NASDAQ: BIIB) following the company's 1Q earnings report. BIIB posted total revenue of $3,131M, missing consensus $3,152M but beating Piper Jaffray's $3,080M estimate. Non-GAAP EPS of $6.05 easily beat consensus $5.93.

BIIB's anti-CD20... More

Nomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS Collaboration

April 23, 2018 8:14 AM EDT

Nomura/Instinet reiterated a Buy rating and $420.00 price target on Biogen (NASDAQ: BIIB) following the company's announced details of an expanded collaboration with IONS to develop CNS-delivered antisense oligonucleotides. The deal was not considered in BIIBs prior financial guidance.

The IONS... More

Ionis Pharmaceuticals (IONS) PT Raised to $75 at BMO Capital on Expanded Biogen Deal

April 20, 2018 9:51 AM EDT

BMO Capital raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $75.00 (from $70.00) while maintaining a Outperform rating.

Analyst Do Kim commented, "We are raising our target price to $75 from $70, as an expanded collaboration with Biogen brings in $1bn cash, consisting of an... More